Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) – September 2015

Anaesthesia Critical Care and Pain Medicine

Volumn 36, Issue 1, 2017, Pages 73-76

  Albaladejo, Pierre ^a   Bonhomme, Fanny ^b   Blais, Normand ^c   Collet, Jean Philippe ^d   Faraoni, David ^e   Fontana, Pierre ^b   Godier, Anne ^f   Llau, Juan ^g   Longrois, Dan ^h   Marret, Emmanuel ⁱ   Mismetti, Patrick ^j   Rosencher, Nadia ^k   Roullet, Stéphanie ^k   Samama, Charles Marc ^l   Schved, Jean François ^m   Sié, Pierre ⁿ   Steib, Annick ^o   Susen, Sophie ^p  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NOTRE DAME HOSPITAL   (Canada)

^d SORBONNE UNIVERSITÉ   (France)

^e HARVARD MEDICAL SCHOOL   (United States)

^f FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h BICHAT HOSPITAL   (France)

ⁱ AMERICAN HOSPITAL OF PARIS   (France)

^j UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^k HÔTEL DIEU   (France)

^l HÔPITAL PELLEGRIN   (France)

^m MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁿ TOULOUSE UNIVERSITY HOSPITAL   (France)

^o UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^p LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Direct oral anticoagulants; Elective surgery; Periprocedural management

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; CREATININE;

ARTICLE; BIOLOGICAL MONITORING; BLEEDING; CREATININE CLEARANCE; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; ELECTIVE SURGERY; HUMAN; INVASIVE PROCEDURE; KIDNEY FUNCTION; NEURAXIAL ANESTHESIA; NEUROSURGERY; PATIENT SAFETY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; REGIONAL ANESTHESIA; RISK; RISK ASSESSMENT; RISK REDUCTION; TREATMENT INTERRUPTION; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD LOSS, SURGICAL; FRANCE; HEMORRHAGE; KIDNEY FUNCTION TEST; LOCAL ANESTHESIA; PHYSIOLOGIC MONITORING; POSTOPERATIVE HEMORRHAGE; PROCEDURES; SURGERY; THROMBOEMBOLISM;

ANESTHESIA, LOCAL; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; CREATININE; ELECTIVE SURGICAL PROCEDURES; FRANCE; HEMORRHAGE; HUMANS; KIDNEY FUNCTION TESTS; MONITORING, PHYSIOLOGIC; NEUROSURGICAL PROCEDURES; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM;

EID: 85006070068     PISSN: None     EISSN: 23525568     Source Type: Journal    
DOI: 10.1016/j.accpm.2016.09.002     Document Type: Article

References (18)

1. [1] Sie, P., Samama, C.M., Godier, A., Rosencher, N., Steib, A., Llau, J.V., et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 104 (2011), 669–676.
2. [2] Sie, P., Samama, C.M., Godier, A., Rosencher, N., Steib, A., Llau, J.V., et al. Chirurgies et actes invasifs chez les patients traites au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d’études sur l'hémostase et la thrombose (GEHT). Ann Fr Anesth Reanim 30 (2011), 645–650.
3. [3] Agence nationale de sécurité du médicament, Les anticoagulants en France en 2014 : état des lieux, synthèse et surveillance. 2014 http://ansm.sante.fr/var/ansm_site/storage/original/application/26ed375830c56499badf0014eb3bb81b.pdf.
4. [4] Garcia, D., Alexander, J.H., Wallentin, L., Wojdyla, D.M., Thomas, L., Hanna, M., et al. Management and clinical outcomes in patients treated with apixaban vs. warfarin undergoing procedures. Blood 124 (2014), 3692–3698.
5. [5] Healey, J.S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (re-ly) randomized trial. Circulation 126 (2012), 343–348.
6. [6] Sherwood, M.W., Douketis, J.D., Patel, M.R., Piccini, J.P., Hellkamp, A.S., Lokhnygina, Y., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor-Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (rocket af). Circulation 129 (2014), 1850–1859.
7. [7] Douketis, J.D., Healey, J.S., Brueckmann, M., Eikelboom, J.W., Ezekowitz, M.D., Fraessdorf, M., et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the re-ly trial. Thromb Haemost 113 (2015), 625–632.
8. [8] Beyer-Westendorf, J., Gelbricht, V., Forster, K., Ebertz, F., Kohler, C., Werth, S., et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden Noac Registry. Eur Heart J 35 (2014), 1888–1896.
9. [9] Schulman, S., Carrier, M., Lee, A.Y., Shivakumar, S., Blostein, M., Spencer, F.A., et al. Perioperative management of dabigatran: a prospective cohort study. Circulation 132 (2015), 167–173.
10. [10] Winkle, R.A., Mead, R.H., Engel, G., Kong, M.H., Patrawala, R.A., Periprocedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace 16 (2014), 1443–1449.
11. [11] Godier, A., Martin, A.C., Leblanc, I., Mazoyer, E., Horellou, M.H., Ibrahim, F., et al. Periprocedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Res 136 (2015), 763–768.
12. [12] Douketis, J.D., Spyropoulos, A.C., Kaatz, S., Becker, R.C., Caprini, J.A., Dunn, A.S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
13. [13] Siegal, D., Yudin, J., Kaatz, S., Douketis, J.D., Lim, W., Spyropoulos, A.C., Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126 (2012), 1630–1639.
14. [14] Haute Autorité de santé, Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier. 2008 http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-09/surdosage_en_avk_situations_a_risque_et_accidents_hemorragiques_-_recommandations_v2.pdf.
15. [15] Douketis, J.D., Spyropoulos, A.C., Spencer, F.A., Mayr, M., Jaffer, A.K., Eckman, M.H., et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141 (2012), e326S–e350S.
16. [16] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., et al. Updated european heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015.
17. [17] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., et al. Ehra practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 34 (2013), 2094–2106.
18. [18] Rosencher, N., Bonnet, M.P., Sessler, D.I., Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 62 (2007), 1154–1160.